The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review-in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement-to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non-cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.
PLASMA AND CRYOPRECIPITATE (CRYO) transfusions have both infectious and noninfectious risks. Whereas most infectious risks are on the order of 1 in 1,000,000, the noninfectious risks-in particular, transfusion-associated circulatory overload and allergic transfusion reactions-are orders of magnitude more common, ranging from 1 in 100 to 1 in 10,000 [1] .
Recent systematic reviews have called into question the efficacy of prophylactic plasma transfusions [2, 3] . Administering fresh frozen plasma (FFP) in patients with minimally elevated International Normalized Ratio (INR) values has been shown to be ineffective in producing meaningful corrections [4, 5] . Commonly recommended doses vary between 10 and 30 mL/kg [6, 7] . At these therapeutic doses, a 70-kg patient might receive between 700 and 2100 mL of plasma. In the right clinical setting, these volumes place patients at risk for transfusion-associated circulatory overload and other adverse outcomes [8] .
As alternatives have emerged, CRYO is now no longer the agent of choice for patients with congenital factor deficiencies. For example, recombinant factor VIII has replaced CRYO in the treatment of hemophilia A. Perhaps the most clinically important remaining use of CRYO is replenishing fibrinogen in patients who develop acquired hypofibrinogenemia intraoperatively. However, despite its widespread use, a recent review published in this Journal [9] concluded that there are insufficient data to guide the appropriate use of CRYO in the perioperative setting.
Prothrombin complex concentrates (PCCs) contain components of the prothrombinase complex-factors II, VII, IX, and X-prepared as a lyophilized powder for reconstitution with small volumes of (ie, 10 -20 mL of Sterile Water for Injection). Different formulations contain varying amounts of proteins C and S, but PCCs are mainly distinguished by their factor VII content. Four-factor concentrates contain clinically significant levels of factor VII; in contrast, 3-factor concentrates have little to none. Examples of 3-factor concentrates include Bebulin (Baxter, Westlake Village, California), Profilnine SD (Grifols Biologicals, Inc, Los Angeles, California), Prothrombinex HT/ VF (CSL Limited, Broadmeadows Victoria, Australia) and Cofact (Sanquin, Amsterdam, the Netherlands). Examples of 4-factor concentrates include Beriplex (CSL Behring, Marburg, Germany), Prothromplex (Immuno, Vienna, Austria), Octaplex (Octapharma, Vienna, Austria), and PPSB-HT (Nihon Pharmaceuticals, Tokyo, Japan). Four-factor concentrates are widely available in several European countries but are not yet available in the US market.
PCCs and fibrinogen concentrates (FIBCs) are used as off-label alternatives to FFP and CRYO to treat acquired coagulopathy in bleeding medical and surgical patients. These concentrates allow for high doses of clotting factors to be administered-unlike therapeutic plasma transfusions-with minimal concerns about volume overload. Because immunoglobulins and other antigenic proteins are removed, these products are ABO neutral and less likely to cause allergic transfusion reactions compared to blood products.
To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review of studies comparing these transfusion alternatives to allogeneic blood transfusion (ABT) in the perioperative setting. Both randomized controlled trials and nonrandomized studies were included for appraisal; however, nonrandomized studies were required to have a comparator group.
Methods

Protocol Registration and Eligibility Criteria
We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement for guidance throughout the entire process of writing this systematic review and registered a protocol online in advance (PROSPERO 2012:CRD42012002599). The PICOS (Population, Intervention, Comparison, Outcomes, Study Design) approach was used to define the criteria for inclusion (Table 1) . Any disagreements between review authors (DL and MT) in the process of study selection and appraisal were resolved by discussion.
Search Strategy and Information Sources
We conducted a systematic literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL (Table A1 in Appendix A). Additional studies were identified by manually searching the reference lists of eligible studies.
Study Selection
Two reviewers (DL and MT) independently screened the titles and abstracts of retrieved records for potential inclusion and then together performed a full text review of the remaining records to exclude studies that did not fulfill the eligibility criteria.
Data Items and Extraction
Two reviewers (DL and MT) extracted the data independently and then together checked for completeness and accuracy. Data extracted included references, funding, details of study design, patient population, primary and comparator intervention(s), and efficacy and safety outcomes. Efficacy outcomes included hematologic parameters and clinical outcomes. Safety outcomes included thromboembolic events and other reported adverse events related to the allocated therapeutic interventions.
Risk of Bias Assessment
Two reviewers (DL and MT) independently assessed the risk of bias using the Cochrane risk of bias tool. In particular, we critically appraised each study by assessing the method of randomization, allocation concealment, whether blinding to intervention was likely to influence efficacy and safety outcomes, whether incomplete outcomes data were addressed, selective outcomes reporting, and potential conflict(s) of interest. The criteria used to assess for high risk of bias are summarized in Table 2 .
Results
Study Selection and Characteristics
The study selection process is depicted in a PRISMA flow diagram (Fig. 1) . Most of the identified records were easily excluded based on relevance by reviewing the title or abstract alone. After this initial screening, records that potentially fulfilled the FIBC (n = 35) and PCC (n = 62) inclusion criteria were selected for full text review. Nine articles from FIBC search and 13 articles from the PCC search were eligible for inclusion. After removing 2 duplicate records, 5 randomized trials and 15 nonrandomized studies with a comparator group were included in our final review. Studies were sorted into 1 of the following 3 clinical settings in Table 3 : cardiac surgery, noncardiac surgery, and reversal of warfarin anticoagulation. Study characteristics are summarized using the PICOS format in Tables 4A,  4B , and 4C.
Cardiac Surgery
Overall, we identified 6 prospective [10] [11] [12] [13] [14] [15] and 2 retrospective [16, 17] studies in the cardiac surgery grouping. Of the 6 prospective studies, 3 were randomized and 3 were nonrandomized. All 8 were single-center studies. Two of the randomized trials assessed the clinical efficacy and safety of FIBC given preoperatively in elective coronary artery bypass graft (CABG) surgery [10] and perioperatively in elective cardiovascular and other major surgery [11] . A third randomized trial assessed the perioperative use of PCC in reversing warfarin anticoagulation and reducing ABT requirements in nonelective cardiac surgery [12] .
Non-Cardiac Surgery
We identified 1 randomized trial and 3 retrospective studies in the non-cardiac surgery grouping. Fenger-Eriksen and colleagues (2009) [18] was a double-blinded randomized trial conducted at a single institution that compared the efficacy of FIBC in reducing perioperative ABT requirement and reversing acquired coagulopathy-as measured by maximum clot firmness (MCF)-induced by hydroxyethyl starch (HES) compared to isotonic sodium chloride solution in elective radical cystectomy for localized bladder cancer. Of the 3 retrospective studies, 2 used data from trauma registries [19, 20] , whereas the third was a single-center study [21] .
Reversal of Warfarin Anticoagulation
We identified 1 randomized trial [22] , 3 prospective studies with historical comparison groups [23] [24] [25] , and 4 retrospective studies Funding source or authors receive fees or honoraria from the manufacturer of hemostatic therapies used in the study.
Intention to treat (ITT). Fig. 1 . PRISMA flow diagram depicting the study selection process. [26] [27] [28] [29] of PCC for warfarin reversal. Six studies [22] [23] [24] [26] [27] [28] specifically assessed the efficacy of PCC in traumatic or spontaneous intracranial hemorrhage, whereas 2 studies [25, 29] focused on reversal of supratherapeutic INR. Boulis and colleagues [22] was an open-label randomized trial conducted at a single institution that compared the time and rate of warfarin reversal in patients with traumatic intracranial bleeding who were treated with 3-factor PCCs or FFP. Both study arms received subcutaneous vitamin K.
Cochrane Risk of Bias Assessment
The risk of bias tool assessment was applied across all studies; and the results are graphically presented in Figures 2A, 2B , and 2C. With the exception of randomized controlled trials by Karlsson and colleagues [10] and Fenger-Eriksen and colleagues [18] , most studies were assessed to have a high degree of methodological bias (Table A2 in Appendix A).
Efficacy and Safety Outcomes in Cardiac Surgery
Five prospective studies in this clinical grouping demonstrated reductions in ABT requirements [10, [12] [13] [14] [15] , of which 4 showed reduction in 24-hour chest tube drainage [10, [13] [14] [15] compared to the comparator arm (Table 5A ). The study by Karlsson and colleagues [10] was assessed to have the lowest overall risk of methodological bias overall; the study reports that a prophylactic 2-g dose of FIBC given preoperatively in patients undergoing elective CABG surgery reduces chest tube drainage postoperatively (P b .01). Although an improved Δ MCF was noted in the study by Lance and colleagues [11] , this difference did not translate to a reduction in ABT utilization. Overall, thrombotic events were similar in both the intervention group and the comparator arm, with an overall low incidence rate [10] [11] [12] [13] [14] [15] .
Two retrospective studies were also appraised. Arnekain and colleagues [16] reported that PCC monotherapy when compared to PCC-FFP combination therapy and FFP monotherapy was the most effective in reducing postoperative chest tube drainage. Gorlinger and colleagues [17] found that a thromboelastometry (TEM)-driven hemostasis protocol in cardiac surgery when compared to an antecedent "no-protocol" period reduced ABT needs. The most significant reduction was in FFP use (1.1% vs 19.4%, P b .001); in addition, composite thromboembolic events were lower (1.77% vs 3.19%, P b .05).
Efficacy and Safety Outcomes in Non-Cardiac Surgery
The only prospective trial in this clinical grouping [18] randomized patients undergoing radical cystectomy to weightbased dosing of FIBC compared to saline control following deliberate hemodilution with HES (Table 5B) . Outcomes demonstrated an overall greater improvement in Δ MCF in the intervention arm; however, there were no differences in intraoperative red cell use between groups, and safety outcomes were not reported. Nevertheless, the study was assessed to have the lowest overall risk of methodological bias in this group.
Two of the retrospective studies in this group [19, 20] compared TEM-guided dosing of FIBC and 4-factor PCC against trauma registry data constituting prevailing clinician practice for patients fulfilling detailed inclusion and exclusion criteria. Patients with major head trauma were excluded from both studies as well as Table 3 Three clinical groupings: cardiac surgery, non-cardiac surgery, and reversal of warfarin anticoagulation Aortic valve and ascending aorta (AV-AA), thoracoabdominal aortic aneurysm (TAAA).
registry patients resuscitated with FIBC and PCC. Two thromboembolic complications occurred in the intervention group of one study [19] , both in association with traumatically injured vessels at the site of thrombosis; safety outcomes were not reported in the latter study [20] .
In the final retrospective study, fibrinogen increments for FIBC and CRYO were compared for medical and surgical patients with acquired hypofibrinogenemia [21] . The mean increment in fibrinogen was greater when equivalent doses of FIBC were administered compared to CRYO. The authors attributed this to variability of fibrinogen concentration between cryoprecipitate pools. Safety was not reported.
Efficacy and Safety Outcomes in Reversal of Warfarin Anticoagulation
One randomized controlled study was reported in this clinical grouping [22] that demonstrated shorter time to INR reversal with PCC, FFP, and subcutaneous vitamin K compared to those who did not receive PCC (2.95 ± 0.46 vs 8.9 ± 1.51 hours, P b .01) (Table 5C ). Whereas no complications were observed in the PCC arm, 5 of the 8 patients in the comparator arm developed complications of fluid overload: 1 case of myocardial infarction, 3 cases of oxygen desaturation (one of whom requiring endotracheal intubation and mechanical ventilation), 2 cases of supraventricular tachycardia, and another case of renal insufficiency from congestive heart failure.
Three prospective studies compared reversal outcomes to retrospective groups [23] [24] [25] . In the 2 focusing on intracranial bleeding [23, 24] , data supported a more rapid and durable INR correction with PCC-based warfarin reversal protocol. Kalina and colleagues [24] reported that 3 patients who received PCC developed deep vein thrombosis (DVT), but no one in the study received Novo-Seven (Novo Nordisk, Inc, Princeton, NJ) -M. Kalina, personal communication.
In the study excluding intracranial hemorrhage in its prospective arm but including it in its historical comparator arm, Holland and colleagues concluded that 3-factor PCC inadequately reverses 2U FFP before CPB; 2U FFP after heparin reversal; no vitamin K (n = 20)
• # of patients achieve INR ≤1.5 Randomized
• Time needed to achieve INR ≤1.5
Open label
• # of patients needing additional hemostasis warfarin anticoagulation [25] . Potentially important confounders include the degree of coagulopathy (mean baseline INR of 9 for the PCC arm and 9.4 for the historical cohort) and the timeframe for follow-up INR testing (mean of 11 hours in the PCC arm compared to 21 hours in the historical cohort).
The retrospective studies comparing PCC to matched historical controls [26] [27] [28] [29] demonstrated reduced subsequent intracerebral hematoma expansion [26, 27] -albeit without major improvements in function-as well as quicker achievement of INR target [27] [28] [29] . Safety outcomes were not reported in 2 studies [26, 27] . The remaining 2 studies report similar incidence of venous thrombotic events (VTEs) [28, 29] . Venous thromboembolic events included 1 case of pulmonary embolism (PE) and 1 case of DVT in the PCC group (occurring on days 8 and 11, respectively; neither patient was receiving VTE prophylaxis) and 1 case of possible stroke in the rVIIa group (which occurred on day 4) [28] . Chapman and colleagues [29] reported 2 DVT cases in the PCC arm (subclavian PICC-line associated and right common femoral DVT in patient with a history of protein S deficiency who sustained a traumatic femur fracture) and 1 DVT case in the comparator cohort (bilateral internal jugular vein DVT with collaterals discovered on day 10 suggestive of chronic venoocclusive disease).
Discussion
In this systematic review, we used the PICOS approach to define the study question and to clarify the eligibility criteria. The strength of our review lies in our specification that all included studies must have a comparator group. This strict criterion resulted in the exclusion of the majority of published articles returned by the search strategy. An additional strength is the rigorous risk of bias assessment based on the Cochrane risk of bias tool. Compared to studies that used PCC to reverse warfarin anticoagulation, FIBC studies more commonly involved conflicts of interest and industry funding. With these latter studies, the sample size in the prospective arms was generally small (mean, 12; range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] ; and the historical comparator cohorts were not well matched to the intervention arm groups. Therefore, with the exception of randomized controlled trials by Karlsson and colleagues (2009) [10] and Fenger-Eriksen and colleagues (2009) [18] , most studies were assessed to have a high degree of methodological bias.
Prospective studies involving FIBC and/or PCC in cardiac surgery were limited by small sample size and potential conflicts of interest. Favorable design elements include randomization [10] [11] [12] , use of an objective method (ie, weighing sponges) to estimate mediastinal bleeding [13, 14] , and an intraoperative transfusion protocol using point-of-care coagulation parameters [13] [14] [15] . Overall, these studies demonstrated a reduction in ABT and chest tube drainage and improved hemostatic laboratory parameters.
It is important to stress that although Demeyere and colleagues [12] reported equivalent mean postintervention INR values at the 1-hour post-cardiopulmonary bypass (CPB) point and equivalent 24-hour chest tube drainage between groups, the comparator FFP arm required considerably more therapeutic measures to reach these targets. All patients (20 of 20) in the plasma arm, compared to only 6 of 20 in the PCC arm, required additional therapies because of failure to achieve INR target or continued bleeding following initial plasma transfusion. Specifically, the FFP arm required 19.4 L additional plasma over the 8 L (400 mL × 20 patients) initially intended as well as additional PCC infusions.
The conclusion in Arnekian and colleagues [16] that low-dose PCC significantly reduced postoperative bleeding in CPB is flawed because of important differences in baseline characteristics. The progressive increase in postoperative bleeding and mortality noted across groups was accompanied by parallel reductions in body mass index (BMI) and increases in the proportion of female patients, preoperative use of clopidogrel, CPB duration, and degree of hemodilution, all of which are important risk factors for bleeding and ABT in cardiac surgery. A similar discrepancy was notable in the retrospective comparator group in Rahe-Meyer and colleagues [14] , with longer CPB duration, lower BMI, and a greater proportion of women compared to the intervention group.
An important point to make about MCF as an end point is that it is a laboratory outcome, rather than a clinical outcome. In addition, standard nephelometric and Clauss-method measurement platforms are less sensitive to HES-induced coagulation defects, whereas TEM is able to detect this specific disturbance [30] . For example, in a study by Urwyler and colleagues [31] , specimens drawn from patients during major surgery were tested in parallel using standard Clauss methodology and TEM. All patients received crystalloids; 89% of patients received HES during surgery. Interestingly, if transfusion decisions had been based upon Clauss-method fibrinogen results, FIBC would be given to none of the 36 patients. However, if transfusion decisions had been based upon TEM guidance, 36% of patients would have received FIBC. This point is critical because it bespeaks the influence of methodology on transfusion practice and because nearly all of the non-warfarin reversal studies reviewed used some aspect of TEM in their treatment algorithms. The importance of methodology is again underscored when interpreting the positive findings in the randomized controlled trial by Fenger-Eriksen and colleagues [18] that compared the effects of FIBC and saline control on MCF (a primary end point) following deliberate hemodilution with HES. Outcomes demonstrated an overall greater improvement in Δ MCF in the intervention arm; however, there were no differences in intraoperative red cell use between groups.
Huttner et al [26] and Kuwashiro et al [27] evaluated intracerebral hematoma growth in a retrospective fashion. In both studies, PCC use was associated with a reduction in hematoma growth but differed in their assessment of functional outcomes. This is likely the result of differences in definition: Huttner et al defined a poor outcome as a modified Rankin Scale (mRS) score of 4 to 6, whereas Intravenous (IV), hematoma expansion (HE), subcutaneous (SQ). Boulis et al. (1999) included 2 nonrandomized cohorts that were not mentioned in the methodology: a retrospective preprotocol cohort (n = 6) and a prospective postprotocol cohort (n = 6).
Kuwashiro et al defined it as 3 to 6. Although Kuwashiro et al reported better clinical outcomes (P = .45) among PCC-treated patients, it is not clear if the differences in functional outcome between groups were clinically meaningful.
Boulis et al [22] reported a major clinically significant safety issue in the FFP arm: importantly, the volume of FFP required for correction with PCC was 399 ± 271 mL compared to 2712 ± 346 mL in the FFPonly arm, leading to significant complications of volume overload in 5 of 8 patients.
Holland and colleagues [25] concluded that 3-factor PCCs do not adequately lower supratherapeutic INR; however, the authors' conclusions may be confounded by multiple factors. Although patients in both arms received vitamin K initially, the routes of administration were noticeably different. Oral, subcutaneous, and intravenous routes were used in 63%, 29%, and 8% of the PCC arm compared to 30%, 61%, and 5% in the FFP arm. Furthermore, subsequent INR measurements were drawn a mean of 11 hours in the PCC arm and 21 hours in the FFP group. A target INR less than 3 at 24 hours was the definition for adequate INR reversal; this target was successfully achieved in 55% of the PCC arm at 11 hours and in about 60% of the FFP arm at 21 hours. It is unclear whether the degree of INR reversal at 11 hours in the PCC arm was due to the initially administered vitamin K or to the PCC infusion. Regardless, based on the 11-hour INR measurement, the PCC arm received FFP; and subsequent INR measurement drawn within 3 hours achieved a success rate of 90%. Finally, the success rate of INR reversal at 21 hours in the FFP arm was equally suboptimal (62%), and this may reflect the preference for subcutaneous administration of vitamin K.
In a randomized controlled study of vitamin K monotherapy for warfarin reversal [32] , patients with baseline INR ranging from 6 to 10 (similar to the study of Holland et al) demonstrated a 50% reduction by 12 hours and correction to INR less than 3 at 24 hours regardless of oral or intravenous route and without FFP or PCC administration. Furthermore, in a pharmacokinetic study of FFP (~12 mL/kg) administered to warfarin-treated participants [33] , the effect of plasma on both factor VII levels and PT measurements peaked at 15 minutes and persisted only for 8 hours. Warfarin rebound effect occurred in all participants by 12 hours and required oral vitamin K for definitive correction.
An alternate interpretation is that the partial INR correction in the PCC arm at 11 hours could be due to either PCC administration or vitamin K administration, that further correction 3 hours after FFP in the PCC group was likely all due to the FFP intervention (and that warfarin rebound effect occurred in at least some of these patients thereafter), and that the suboptimal INR correction (only 60% of patients with INR b 3 at 21 hours) in the FFP arm was in large part likely the result of the suboptimal route of administration (subcutaneous) used in the majority (60%) of these patients. Therefore, an important consideration during warfarin reversal is the route of administration of vitamin K. The preferred routes of administration are intravenous and oral, with the oral route demonstrating a somewhat delayed initial onset of effect compared to intravenous but similar responses by 24 hours [32] . A recent expert review [34] advised against the use of subcutaneous vitamin K because of its unpredictable and suboptimal effect.
Conclusion
Preferred primary end points are patient-related clinical outcomes, such as perioperative ABT needs, postoperative chest tube drainage, and level of functioning as measured by mRS. Less meaningful end points are laboratory parameters, such as Δ in fibrinogen, MCF, or INR, as these represent surrogate markers of clinical efficacy. Safety outcomes are difficult to estimate especially in prospective trials because of the relatively low incidence of intervention-related adverse events.
For studies involving FIBC alone or combined with PCC, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. The majority of studies using FIBC based their decision-making upon TEM results, which may be more sensitive to fibrinogen defects or deficits than Clauss-based methods and therefore may significantly influence transfusion decision.
Prospective studies, primarily in the cardiac surgery setting, appear to support a reduction in allogeneic exposures and more rapid achievement of laboratory-based hemostatic targets but were underpowered to support firm conclusions about the risk-benefit ratio of FIBC and PCC. Instead, these studies may be thought of as feasibility studies or initial new drug studies to support future randomized, controlled, adequately powered studies.
Large retrospective studies comparing preprotocol to postprotocol implementation of concentrate-based resuscitation in the perioperative setting support a reduction in ABT, predominantly because such protocols exchange PCC and/or CRYO for FFP. Another consideration is that these studies represent a comparison of practice between single centers in which a culture of blood conservation has already been established against registry data that are representative of the wide variation in transfusion practice in various regions.
The assessment of safety outcomes was not uniform and raises concerns of underreporting. Adverse events that did occur, however, could also be attributed to underlying patient-specific factors (underlying inherited thrombophilia) or clinical circumstances (eg,. lack of pharmacologic DVT prophylaxis). The largest study reviewed by Gorlinger and colleagues [17] demonstrated no increase in mortality or thromboembolic outcomes despite an increase in use of FIBC and PCC during the postimplementation period.
In terms of warfarin reversal, PCCs more rapidly corrected INR than plasma. In the setting of intracranial hemorrhage, functional outcomes were poor regardless of reversal strategy. Efficacy of INR reversal should take into account the baseline INR, the pharmacokinetic aspects of the reversal strategy (onset and duration of effect), and the potential for INR rebound when short-acting strategies are implemented. Definitive warfarin reversal requires the utilization of vitamin K, preferably via the intravenous or oral route.
Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients. Such studies would require stratification of important differences in bleeding based upon the population and surgical setting being studied for example, body surface area, preoperative anemia, and female sex in the setting of cardiac surgery. They would additionally be enhanced by attempts to objectively measure surgical and postoperative blood loss and ABT between groups. Transfusion protocols would be applied to both groups and would be driven by both clinical outcomes and point-of-care laboratory measurements. [18] FIBC arm (n = 11) Placebo arm (n = 10) Safety not reported Δ in MCF is higher (no numeric value)⁎ Lower (no numeric value) Intraop RBC needs = 2 U (0 to 5) 2.5 (0 to 6) 48-h postop RBC needs = 0 U (0 to 2)⁎ 1.5 (0 to 2) Nienaber (2011) [19] FIBC + PCC arm (n = 
Cardiac Surgery
No study completely fulfilled the 8 predefined criteria for low risk of bias (Fig. 2A) ; however, the study by Karlsson et al [10] fulfilled 6 of the 8 criteria for low risk of bias but was high risk of bias for analyzing the results not with intention to treat and receiving financial support from CSL Behring. Two other randomized trials were at high risk of bias or provided inadequate information regarding methods of randomization, allocation concealment, and blinding [11, 12] . Three nonrandomized studies had differences in clinically important baseline characteristics between the study arms that potentially confound the observed study effect [13, 15, 16] . For example, in the study by Arnekian et al (2012) , women had lower BMI and so were at an increased risk of ABT requirement during CPB. No study prospectively compared FIBC with cryoprecipitate, the most directly comparable allogeneic blood component therapy. Instead, 7 of 8 studies compared FIBC to FFP alone or protocol-based ABT guideline; and 1 study compared preoperative FIBC to no hemostatic therapy [10] . Lastly, 7 of 8 studies reported financial support from CSL Behring, except for Arnekian et al [16] .
Non-Cardiac Surgery
No study completely fulfilled the 8 predefined criteria for low risk of bias (Fig. 2B) ; however, the study by Fenger-Eriksen et al [18] fulfilled 6 of the 8 criteria for low risk of bias but was at high risk of bias for analyzing the results not with intention to treat and receiving financial support from CSL Behring. Differences in transfusion protocol [19] , differences in clinically important baseline characteristics [20] , and variability in the timing of fibrinogen measurement [21] between study arms potentially confound the observed study effects. Of note, only Theodoulou et al [21] directly compared FIBC with cryoprecipitate, albeit retrospectively.
Reversal of Warfarin Anticoagulation
No study completely fulfilled the 8 predefined criteria for low risk of bias. The only randomized trial in this clinical grouping was at high risk of bias for lack of allocation concealment, for unblinded providers and assessors, and for analyzing results not with intention to treat [22] . Variability in the timing of INR measurement makes the therapeutic effect of FFP, PCC, and vitamin K on warfarin reversal difficult to interpret [23, 24, 25, 29] . Differences in clinically important baseline characteristics-baseline INR, proportion of traumatic bleeding-between study arms potentially confound the observed study effect in Pinner et al [28] . Hemostatic therapy was discretionary in all 4 retrospective studies; dosing was not guided by an institutional transfusion protocol [26, 27, 28, 29] . [28] PCC arm (n = 9) rVIIa arm (n = 15) PCC arm = 1 PE, 1 DVT INR ≤1.3 at 6 h = 50% (3/6) 93% (14/15) rFVIIa arm = 1 possible stroke HE on repeat CT = 11% (1/9) 20% (3/15) ⁎ P b .05 compared between groups. ⁎⁎ P b .01 compared between groups. ⁎⁎⁎ P b .001 compared between groups. (continued on next page) 
